9656
document
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction . Short-acting beta ( 2 ) -agonists are currently recommended for symptom relief in asthma and the treatment of mild , acute exacerbations in COPD . However , formoterol has as fast an onset of action as salbutamol with the additional benefit of longer-lasting bronchodilation ( approximately 12 h ) . Furthermore , systemic side effects observed with formoterol are of a similar duration but less pronounced than with short-acting beta ( 2 ) -agonists . In this double-blind , randomized , cross-over study , 20 adult patients with reversible chronic airway obstruction ( intrinsic asthma or COPD ) inhaled single doses of formoterol 9 microg or salbutamol 100 microg ( group A ) or formoterol 18 microg or salbutamol 200 microg ( group B ) . FEV ( 1 ) was measured prior to and 5 , 10 , 15 , 20 , 25 and 30 min following inhalation of study drug . No significant differences in FEV ( 1 ) values were observed between group A ( P=0.704 ) or group B ( P=0.270 ) at baseline , or at 5 ( Group A : P=0.340 ; Group B : P=0.559 ) and 15 min ( Group A : P=0.526 ; Group B : P=0.818 ) post dose . No adverse events were reported during the study . Formoterol Turbuhaler has as rapid an onset of action as salbutamol pMDI when given at the recommended doses .
9657
Intervention_Pharmacological
formoterol
9658
Intervention_Pharmacological
salbutamol
9659
Intervention_Pharmacological
formoterol
9660
Intervention_Pharmacological
salbutamol
9661
Intervention_Pharmacological
formoterol
9662
Intervention_Pharmacological
formoterol 9 microg
9663
Intervention_Pharmacological
salbutamol 100 microg ( group A )
9664
Intervention_Pharmacological
formoterol 18 microg
9665
Intervention_Pharmacological
salbutamol 200 microg
9666
Intervention_Pharmacological
Formoterol
9667
Intervention_Pharmacological
salbutamol
9668
Outcome_Physical
FEV ( 1 )
9669
Outcome_Physical
FEV ( 1 )
9670
Outcome_Adverse-effects
adverse events
9671
Participant_Condition
reversible chronic airway obstruction .
9672
Participant_Condition
20 adult patients with reversible chronic airway obstruction ( intrinsic asthma or COPD )